Genetic Technologies Limited (AU:GTG) has released an update.
Genetic Technologies Limited has launched a new suite of precision oncology tests through its geneType brand, aimed at enhancing personalized treatment and improving patient outcomes in various cancers. The tests, which span liquid biopsies, mutation, and methylation assessments, are poised to revolutionize cancer diagnostics and monitoring, with a strategic plan to ensure patient accessibility and affordability. The company is tapping into a rapidly growing genomics market, with the potential to significantly impact the healthcare system by offering more accurate, personalized diagnostic solutions.
For further insights into AU:GTG stock, check out TipRanks’ Stock Analysis page.
